{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:10:10Z","timestamp":1782141010140,"version":"3.54.5"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ejmech.2020.112855","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T22:52:56Z","timestamp":1600469576000},"page":"112855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Modern trends in diuretics development"],"prefix":"10.1016","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4305-3674","authenticated-orcid":false,"given":"Tetiana","family":"Titko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Perekhoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Drapak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgen","family":"Tsapko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112855_bib1","doi-asserted-by":"crossref","first-page":"111852","DOI":"10.1016\/j.ejmech.2019.111852","article-title":"A\u00a0concise review of recent advances in anti-heart failure targets and its small molecules inhibitors in recent years","volume":"186","author":"Li","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib2","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/HJH.0000000000002088","article-title":"Redefining diuretics use in hypertension: why select a thiazide-like diuretic?","volume":"37","author":"Burnier","year":"2019","journal-title":"J.\u00a0Hypertens."},{"key":"10.1016\/j.ejmech.2020.112855_bib3","series-title":"Diuretic Agents: Clinical Physiology and Pharmacology","author":"Seldin","year":"1997"},{"key":"10.1016\/j.ejmech.2020.112855_bib4","series-title":"Textbook of Nephro-Endocrinology","first-page":"465","article-title":"Chapter 26 - aldosterone: history and introduction","author":"Gotoh","year":"2017"},{"key":"10.1016\/j.ejmech.2020.112855_bib5","series-title":"Medical Pharmacology and Therapeutics","first-page":"219","article-title":"14 - diuretics","author":"Waller","year":"2017"},{"key":"10.1016\/j.ejmech.2020.112855_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion \u2014 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejmech.2020.112855_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/CRD.0000000000000116","article-title":"Treating diuretic resistance: an overview","volume":"24","author":"Bowman","year":"2016","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.ejmech.2020.112855_bib8","series-title":"Comprehensive Medicinal Chemistry II","first-page":"575","article-title":"6.25 - Renal Dysfunction in Hypertension and Obesity","author":"Elmarakby","year":"2007"},{"key":"10.1016\/j.ejmech.2020.112855_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192990","article-title":"Loop diuretics are associated with greater risk of sarcopenia in patients with non-dialysis-dependent chronic kidney disease","volume":"13","author":"Ishikawa","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2020.112855_bib10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cpt.754","article-title":"Emerging targets of diuretic therapy","volume":"102","author":"Cheng","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2020.112855_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev-med-050913-022838","article-title":"Vasopressin receptor antagonists, heart failure, and polycystic kidney disease","volume":"66","author":"Torres","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2020.112855_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","article-title":"Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors","volume":"8","author":"Oliva","year":"2014","journal-title":"J.\u00a0Am. Soc. Hypertens."},{"key":"10.1016\/j.ejmech.2020.112855_bib13","first-page":"292","article-title":"Use of \u201cVaptans\u201d in treatment of hyponatremia","volume":"43","author":"Tanindi","year":"2015","journal-title":"Arch. Turkish Soc. Cardiol."},{"key":"10.1016\/j.ejmech.2020.112855_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/2229-516X.106347","article-title":"Vaptans: a new option in the management of hyponatremia","volume":"2","author":"Aditya","year":"2012","journal-title":"Int. J. Appl. Basic Med. Res."},{"key":"10.1016\/j.ejmech.2020.112855_bib15","author":"Satavaptan - AdisInsight"},{"key":"10.1016\/j.ejmech.2020.112855_bib16","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1021\/acs.jmedchem.7b00422","article-title":"Tolvaptan-type vasopressin receptor ligands: important role of axial chirality in the active form","volume":"60","author":"Tabata","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib17","series-title":"Mod. Drug Synth.","first-page":"175","article-title":"Conivaptan (Vaprisol): vasopressin via and V2 antagonist for hyponatremia","author":"Lanman","year":"2010"},{"key":"10.1016\/j.ejmech.2020.112855_bib18","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1021\/jm960133o","article-title":"Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds","volume":"39","author":"Ogawa","year":"1996","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib19","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0968-0896(99)00101-7","article-title":"7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist","volume":"7","author":"Kondo","year":"1999","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib20","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1021\/jm980179c","article-title":"5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)- ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors [2]","volume":"41","author":"Albright","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.cardfail.2008.06.003","article-title":"Efficacy and safety of the vasopressin V1A\/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study","volume":"14","author":"Goldsmith","year":"2008","journal-title":"J.\u00a0Card. Fail."},{"key":"10.1016\/j.ejmech.2020.112855_bib22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0735-1097(16)31320-1","article-title":"Treatment with the V1a\/V2-vasopressin receptor antagonist conivaptan increases cardiac output during exercise in patients with advanced heart failure","volume":"67","author":"Balling","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2020.112855_bib23","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.ihj.2015.10.386","article-title":"Decongestion: diuretics and other therapies for hospitalized heart failure","volume":"68","author":"Vazir","year":"2016","journal-title":"Indian Heart J."},{"key":"10.1016\/j.ejmech.2020.112855_bib24","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.ejmech.2020.112855_bib25","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jacc.2016.09.005","article-title":"Tolvaptan in acute heart failure: time to move on","volume":"69","author":"Starling","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2020.112855_bib26","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2020.112855_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2478\/jce-2019-0007","article-title":"Efficacy of tolvaptan in elderly patients with heart failure and preserved ejection fraction","volume":"5","author":"Suzuki","year":"2019","journal-title":"J.\u00a0Cardiovasc. Emergencies."},{"key":"10.1016\/j.ejmech.2020.112855_bib28","author":"ClinicalTrialsgov"},{"key":"10.1016\/j.ejmech.2020.112855_bib29","author":"ClinicalTrialsgov"},{"key":"10.1016\/j.ejmech.2020.112855_bib30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/ijms21010183","article-title":"Lixivaptan, a new generation diuretic, counteracts vasopressin-induced aquaporin-2 trafficking and function in renal collecting duct cells","volume":"21","author":"Di Mise","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2020.112855_bib31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cardfail.2017.12.011","article-title":"Dual vasopressin V1a\/V2 antagonism: the next step in neurohormonal modulation in patients with heart failure?","volume":"24","author":"Goldsmith","year":"2018","journal-title":"J.\u00a0Card. Fail."},{"key":"10.1016\/j.ejmech.2020.112855_bib32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/2047487318755531","article-title":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis","volume":"25","author":"Usman","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ejmech.2020.112855_bib33","article-title":"Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume","volume":"8","author":"Masuda","year":"2020","journal-title":"Phys. Rep."},{"key":"10.1016\/j.ejmech.2020.112855_bib34","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1039\/C9RA08706K","article-title":"SGLT inhibitors as antidiabetic agents: a comprehensive review","volume":"10","author":"Kshirsagar","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2020.112855_bib35","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3390\/molecules21091136","article-title":"Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents","volume":"21","author":"Choi","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2020.112855_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s41061-019-0243-6","article-title":"In the search of glycoside-based molecules as antidiabetic agents","volume":"377","author":"Pa\u0142asz","year":"2019","journal-title":"Top. Curr. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/1573406411666150105105529","article-title":"Design of SGLT2 inhibitors for the treatment of type 2 diabetes: a history driven by biology to chemistry","volume":"11","author":"Cai","year":"2015","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib38","doi-asserted-by":"crossref","first-page":"111773","DOI":"10.1016\/j.ejmech.2019.111773","article-title":"Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: a review","volume":"184","author":"Haider","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib39","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1021\/jm100332n","article-title":"Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"53","author":"Nomura","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib40","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1016\/j.bmc.2013.05.048","article-title":"C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors","volume":"21","author":"Koga","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib41","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s13300-019-0566-x","article-title":"Ertugliflozin compared to other anti-hyperglycemic agents as monotherapy and add-on therapy in type 2 diabetes: a systematic literature review and network meta-analysis","volume":"10","author":"McNeill","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ejmech.2020.112855_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2014.40","article-title":"Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin","volume":"4","author":"Haas","year":"2014","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.ejmech.2020.112855_bib43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/DMSO.S184437","article-title":"Canagliflozin review \u2013 safety and efficacy profile in patients with T2DM","volume":"12","author":"Jakher","year":"2019","journal-title":"Diabetes, Metab. Syndrome Obes. Targets Ther."},{"key":"10.1016\/j.ejmech.2020.112855_bib44","author":"ClinicalTrialsgov"},{"key":"10.1016\/j.ejmech.2020.112855_bib45","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.119.042685","article-title":"Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus","volume":"140","author":"Berg","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2020.112855_bib46","author":"ClinicalTrialsgov"},{"key":"10.1016\/j.ejmech.2020.112855_bib47","author":"ClinicalTrialsgov"},{"key":"10.1016\/j.ejmech.2020.112855_bib48","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1681\/ASN.2019090944","article-title":"A\u00a0randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis","volume":"31","author":"Refardt","year":"2020","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2020.112855_bib49","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1016\/j.bmcl.2010.07.095","article-title":"Identification and optimization of substituted 5-aminopyrazoles as potent and selective adenosine A1 receptor antagonists","volume":"20","author":"Griebenow","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112855_bib50","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.bmc.2017.02.029","article-title":"Design and synthesis of novel, potent and selective hypoxanthine analogs as adenosine A1 receptor antagonists and their biological evaluation","volume":"25","author":"Koul","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib51","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbamem.2010.12.017","article-title":"Recent developments in adenosine receptor ligands and their potential as novel drugs","volume":"1808","author":"M\u00fcller","year":"2011","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ejmech.2020.112855_bib52","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cardfail.2008.08.010","article-title":"The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment","volume":"14","author":"Cotter","year":"2008","journal-title":"J.\u00a0Card. Fail."},{"key":"10.1016\/j.ejmech.2020.112855_bib53","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","article-title":"Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure","volume":"363","author":"Massie","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.112855_bib54","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1517\/14656566.2010.514605","article-title":"Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure","volume":"11","author":"Ensor","year":"2010","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2020.112855_bib55","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ahj.2011.03.004","article-title":"Rationale, design, and results from RENO-DEFEND 1: a randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure","volume":"161","author":"Pang","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejmech.2020.112855_bib56","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/ki.2010.204","article-title":"Adenosine A1 receptor antagonists in clinical research and development","volume":"78","author":"Hocher","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2020.112855_bib57","author":"ClinicalTrialsgov"},{"key":"10.1016\/j.ejmech.2020.112855_bib58","author":"ClinicalTrialsgov"},{"key":"10.1016\/j.ejmech.2020.112855_bib59","series-title":"Sodium and Water Homeostasis: Comparative, Evolutionary and Genetic Models","author":"Hyndman","year":"2015"},{"key":"10.1016\/j.ejmech.2020.112855_bib60","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2013.08.005","article-title":"A\u00a0small molecule screen identifies selective inhibitors of urea transporter UT-A","volume":"20","author":"Esteva-Font","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112855_bib61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nrneph.2014.219","article-title":"Urea transporter proteins as targets for small-molecule diuretics","volume":"11","author":"Esteva-Font","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejmech.2020.112855_bib62","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ki.2013.94","article-title":"Urea channel inhibitors: a new functional class of aquaretics","volume":"83","author":"Knepper","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2020.112855_bib63","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.2006101108","article-title":"Urea and renal function in the 21st century: insights from knockout mice","volume":"18","author":"Fenton","year":"2007","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2020.112855_bib64","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1096\/fj.14-253872","article-title":"Diuresis and reduced urinary osmolality in rats produced by small-molecule UT-A-selective urea transport inhibitors","volume":"28","author":"Esteva-Font","year":"2014","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2020.112855_bib65","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/ki.2013.62","article-title":"A\u00a0novel small-molecule thienoquinolin urea transporter inhibitor acts as a potential diuretic","volume":"83","author":"Li","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2020.112855_bib66","doi-asserted-by":"crossref","first-page":"F1363","DOI":"10.1152\/ajprenal.00421.2014","article-title":"Thienoquinolins exert diuresis by strongly inhibiting UT-A urea transporters","volume":"307","author":"Ren","year":"2014","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejmech.2020.112855_bib67","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/pharmaceutics10030124","article-title":"Pharmacokinetics, tissue distribution and excretion of a novel diuretic (PU-48) in rats","volume":"10","author":"Zhang","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2020.112855_bib68","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejmech.2019.03.060","article-title":"Discovery and optimization of thienopyridine derivatives as novel urea transporter inhibitors","volume":"172","author":"Zhao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib69","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41401-019-0245-5","article-title":"A\u00a0thienopyridine, CB-20, exerts diuretic activity by inhibiting urea transporters","volume":"41","author":"Li","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2020.112855_bib70","first-page":"1","article-title":"Developing hypothetical inhibition mechanism of novel urea transporter B inhibitor","volume":"4","author":"Li","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2020.112855_bib71","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/aps.2016.4","article-title":"Phenylphthalazines as small-molecule inhibitors of urea transporter UT-B and their binding model","volume":"37","author":"Ran","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2020.112855_bib72","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1096\/fj.06-6979com","article-title":"Urearetics: a small molecule screen yields nanomolar potency inhibitors of urea transporter UT-B","volume":"21","author":"Levin","year":"2007","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2020.112855_bib73","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1681\/ASN.2011070751","article-title":"Triazolothienopyrimidine inhibitors of urea transporter UT-B reduce urine concentration","volume":"23","author":"Yao","year":"2012","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2020.112855_bib74","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1021\/jm300491y","article-title":"Nanomolar potency and metabolically stable inhibitors of kidney urea transporter UT-B","volume":"55","author":"Anderson","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib75","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1039\/C5MD00198F","article-title":"Discovery, synthesis and structure-activity analysis of symmetrical 2,7-disubstituted fluorenones as urea transporter inhibitors","volume":"6","author":"Lee","year":"2015","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2020.112855_bib76","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1021\/acs.jmedchem.8b00343","article-title":"Nanomolar-potency 1,2,4-triazoloquinoxaline inhibitors of the kidney urea transporter UT-A1","volume":"61","author":"Lee","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib77","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/ki.2015.138","article-title":"Salt-sparing diuretic action of a water-soluble urea analog inhibitor of urea transporters UT-A and UT-B in rats","volume":"88","author":"Cil","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2020.112855_bib78","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.chembiol.2013.10.003","article-title":"Urea transporter inhibitors: en route to new diuretics","volume":"20","author":"Sands","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112855_bib79","series-title":"Vitam. Horm.","first-page":"105","article-title":"Aldosterone and ion channels","author":"Valinsky","year":"2019"},{"key":"10.1016\/j.ejmech.2020.112855_bib80","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2174\/0929867324666171012120937","article-title":"The renal outer medullary potassium channel (ROMK): an intriguing pharmacological target for an innovative class of diuretic drugs","volume":"25","author":"Calderone","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib81","doi-asserted-by":"crossref","first-page":"8682","DOI":"10.1021\/acs.jmedchem.8b01891","article-title":"Discovery of small molecule renal outer medullary potassium (ROMK) channel inhibitors: a brief history of medicinal chemistry approaches to develop novel diuretic therapeutics","volume":"62","author":"Aretz","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib82","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1124\/mol.117.108472","article-title":"Pore polarity and charge determine differential block of Kir1.1 and Kir7.1 potassium channels by small-molecule inhibitor VU590","volume":"92","author":"Kharade","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112855_bib83","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/jpet.113.208603","article-title":"Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresiss","volume":"348","author":"Garcia","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112855_bib84","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1021\/acsmedchemlett.6b00122","article-title":"Discovery of MK-7145, an oral small molecule ROMK inhibitor for the treatment of hypertension and heart failure","volume":"7","author":"Tang","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112855_bib85","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.bmcl.2016.10.032","article-title":"The design and synthesis of novel spirocyclic heterocyclic sulfone ROMK inhibitors as diuretics","volume":"27","author":"Chobanian","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112855_bib86","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/j.bmcl.2017.03.086","article-title":"Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores","volume":"27","author":"Dong","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112855_bib87","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1021\/acsmedchemlett.7b00481","article-title":"Discovery and in\u00a0vitro optimization of 3-sulfamoylbenzamides as ROMK inhibitors","volume":"9","author":"Sammons","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112855_bib88","author":"ClinicalTrialsgov"},{"key":"10.1016\/j.ejmech.2020.112855_bib89","series-title":"Comprehensive Medicinal Chemistry III","first-page":"308","article-title":"Discovery of ROMK Inhibitor MK-7145: A Novel Mechanism Diuretic","author":"Pasternak","year":"2017"},{"key":"10.1016\/j.ejmech.2020.112855_bib90","author":"ClinicalTrialsgov"},{"key":"10.1016\/j.ejmech.2020.112855_bib91","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/cmdc.201700425","article-title":"WNK signaling inhibitors as potential antihypertensive drugs","volume":"12","author":"AlAmri","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.112855_bib92","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1681\/ASN.2010090926","article-title":"An emerging role for SPAK in NCC, NKCC, and blood pressure regulation","volume":"21","author":"Rodan","year":"2010","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2020.112855_bib93","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1681\/ASN.2014060560","article-title":"Discovery of novel SPAK inhibitors that block WNK kinase signaling to cation chloride transporters","volume":"26","author":"Kikuchi","year":"2015","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2020.112855_bib94","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/cmdc.201700077","article-title":"Rafoxanide and closantel inhibit SPAK and OSR1 kinases by binding to a highly conserved allosteric site on their C-terminal domains","volume":"12","author":"AlAmri","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.112855_bib95","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/cbic.201800272","article-title":"The photosensitising clinical agent verteporfin is an inhibitor of SPAK and OSR1 kinases","volume":"19","author":"AlAmri","year":"2018","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2020.112855_bib96","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1042\/BJ20130597","article-title":"Chemical library screening for WNK signalling inhibitors using fluorescence correlation spectroscopy","volume":"455","author":"Mori","year":"2013","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2020.112855_bib97","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1016\/j.bmc.2017.05.034","article-title":"Development of WNK signaling inhibitors as a new class of antihypertensive drugs","volume":"25","author":"Ishigami-Yuasa","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib98","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/cbic.201600620","article-title":"Towards the development of small-molecule MO25 binders as potential indirect SPAK\/OSR1 kinase inhibitors","volume":"18","author":"Kadri","year":"2017","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2020.112855_bib99","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1021\/acschembio.6b00511","article-title":"Discovery and characterization of allosteric WNK kinase inhibitors","volume":"11","author":"Yamada","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112855_bib100","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1016\/j.arabjc.2020.02.010","article-title":"Pharmacoinformatics and molecular dynamic simulation studies to identify potential small-molecule inhibitors of WNK-SPAK\/OSR1 signaling that mimic the RFQV motifs of WNK kinases","volume":"13","author":"Alamri","year":"2020","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib101","first-page":"1597","article-title":"WNK-SPAK-SLC12A signal cascade is a new therapeutic target for hypertension","volume":"73","author":"Kikuchi","year":"2015","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.ejmech.2020.112855_bib102","series-title":"Handb. Horm. Comp. Endocrinol. Basic Clin. Res.","first-page":"281","article-title":"Subchapter 32A - atrial natriuretic peptide","author":"Takei","year":"2016"},{"key":"10.1016\/j.ejmech.2020.112855_bib103","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.peptides.2018.08.006","article-title":"Natriuretic peptides in human heart: novel insight into their molecular forms, functions, and diagnostic use","volume":"111","author":"Matsuo","year":"2019","journal-title":"Peptides"},{"key":"10.1016\/j.ejmech.2020.112855_bib104","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ejhf.698","article-title":"Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure","volume":"19","author":"Packer","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejmech.2020.112855_bib105","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","article-title":"Effect of ularitide on cardiovascular mortality in acute heart failure","volume":"376","author":"Packer","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.112855_bib106","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/TCRM.S179302","article-title":"New therapies for the treatment of heart failure: a summary of recent accomplishments","volume":"15","author":"Machaj","year":"2019","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ejmech.2020.112855_bib107","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1590\/S0100-879X2004000800015","article-title":"Imidazoline receptors in the heart: a novel target and a novel mechanism of action that involves atrial natriuretic peptides","volume":"37","author":"Mukaddam-Daher","year":"2004","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.ejmech.2020.112855_bib108","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jff.2017.10.037","article-title":"Geniposidic acid upregulates atrial natriuretic peptide secretion and lowers blood pressure in spontaneously hypertensive rats","volume":"40","author":"Nakamura","year":"2018","journal-title":"J.\u00a0Funct. Foods."},{"key":"10.1016\/j.ejmech.2020.112855_bib109","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.bmc.2017.01.026","article-title":"Discovery and dimeric approach of novel Natriuretic Peptide Receptor A (NPR-A) agonists","volume":"25","author":"Iwaki","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib110","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1016\/j.bmcl.2017.09.028","article-title":"Discovery and SAR of a novel series of natriuretic peptide receptor-A (NPR-A) agonists","volume":"27","author":"Iwaki","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112855_bib111","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1016\/j.bmc.2017.11.006","article-title":"Discovery and in\u00a0vivo effects of novel human natriuretic peptide receptor A (NPR-A) agonists with improved activity for rat NPR-A","volume":"25","author":"Iwaki","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib112","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1139\/y11-054","article-title":"Guanylyl cyclase\/atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation","volume":"89","author":"Pandey","year":"2011","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112855_bib113","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1152\/advan.00177.2016","article-title":"The renal and cardiovascular effects of natriuretic peptides","volume":"41","author":"Wong","year":"2017","journal-title":"Adv. Physiol. Educ."},{"key":"10.1016\/j.ejmech.2020.112855_bib114","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1681\/ASN.2012080787","article-title":"Overexpression of pendrin in intercalated cells produces chloride-sensitive hypertension","volume":"24","author":"Jacques","year":"2013","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2020.112855_bib115","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1681\/ASN.2016070720","article-title":"Pendrin-A new target for diuretic therapy?","volume":"27","author":"Wagner","year":"2016","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2020.112855_bib116","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000335117","article-title":"Pendrin as a novel target for diuretic therapy","volume":"28","author":"Amlal","year":"2011","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2020.112855_bib117","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.4049\/jimmunol.178.8.5144","article-title":"Thiocyanate transport in resting and IL-4-stimulated human bronchial epithelial cells: role of pendrin and anion channels","volume":"178","author":"Pedemonte","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ejmech.2020.112855_bib118","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1159\/000445559","article-title":"Effect of known inhibitors of ion transport on pendrin (SLC26A4) activity in a human kidney cell line","volume":"38","author":"Bernardinelli","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2020.112855_bib119","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1096\/fj.201600223R","article-title":"Inhibitors of pendrin anion exchange identified in a small molecule screen increase airway surface liquid volume in cystic fibrosis","volume":"30","author":"Haggie","year":"2016","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2020.112855_bib120","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.bmcl.2019.07.003","article-title":"Synthesis and evaluation of tetrahydropyrazolopyridine inhibitors of anion exchange protein SLC26A4 (pendrin)","volume":"29","author":"Zhu","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112855_bib121","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1681\/ASN.2015121312","article-title":"Small-molecule inhibitors of pendrin potentiate the diuretic action of furosemide","volume":"27","author":"Cil","year":"2016","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2020.112855_bib122","series-title":"An Introduction to Biological Membranes: Composition, Structure and Function","author":"Stillwell","year":"2016"},{"key":"10.1016\/j.ejmech.2020.112855_bib123","doi-asserted-by":"crossref","first-page":"F193","DOI":"10.1152\/ajprenal.00304.2019","article-title":"Aquaporins in the kidney: physiology and pathophysiology","volume":"318","author":"Su","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejmech.2020.112855_bib124","series-title":"Nephrol. Fluid\/Electrolyte Physiol.","first-page":"189","article-title":"Chapter 12 - renal modulation: arginine vasopressin and atrial natriuretic peptide","author":"de Jes\u00fas-Gonz\u00e1lez","year":"2019"},{"key":"10.1016\/j.ejmech.2020.112855_bib125","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/cbdd.12713","article-title":"Rapid identification of novel inhibitors of the human aquaporin-1 water channel","volume":"87","author":"Patil","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2020.112855_bib126","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3390\/ijms20071589","article-title":"Inhibitors of mammalian aquaporin water channels","volume":"20","author":"Abir-Awan","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2020.112855_bib127","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/mol.108.053744","article-title":"Inhibition of aquaporin-1 and aquaporin-4 water permeability by a derivative of the loop diuretic bumetanide acting at an internal pore-occluding binding site","volume":"76","author":"Migliati","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112855_bib128","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1681\/ASN.2012080869","article-title":"AqF026 is a pharmacologic agonist of the water channel aquaporin-1","volume":"24","author":"Yool","year":"2013","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2020.112855_bib129","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bmc.2007.12.038","article-title":"Inhibition of Aquaporin 4 by antiepileptic drugs","volume":"17","author":"Huber","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112855_bib130","series-title":"Aquaporins. Adv. Exp. Med. Biol.","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-94-024-1057-0_16","article-title":"Aquaporin-targeted therapeutics: state-of-the-field","author":"Tradtrantip","year":"2017"},{"key":"10.1016\/j.ejmech.2020.112855_bib131","doi-asserted-by":"crossref","first-page":"55","DOI":"10.32352\/0367-3057.2.19.06","article-title":"Synthesis, diuretic activity research and QSAR-analysis of N-(1,3,4-tiadiazol-2-il)substituted amides of alkanecarboxylic acids","volume":"2","author":"Drapak","year":"2019","journal-title":"Farm. Zh. (Kiev)"},{"key":"10.1016\/j.ejmech.2020.112855_bib132","doi-asserted-by":"crossref","first-page":"125","DOI":"10.22159\/ijap.2019v11i5.33873","article-title":"Development and validation of LC-MS\/MS method for estimation of urocarb in human plasma","volume":"11","author":"Drapak","year":"2019","journal-title":"Int. J. Appl. Pharm."},{"key":"10.1016\/j.ejmech.2020.112855_bib133","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/cb300153z","article-title":"Discovery of novel human aquaporin-1 blockers","volume":"8","author":"Seeliger","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112855_bib134","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.bbagen.2015.05.019","article-title":"A\u00a0generic high-throughput assay to detect aquaporin functional mutants: potential application to discovery of aquaporin inhibitors","volume":"1850","author":"To","year":"2015","journal-title":"Biochim. Biophys. Acta Gen. Subj."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420308278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420308278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:22:02Z","timestamp":1759328522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420308278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":134,"alternative-id":["S0223523420308278"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112855","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modern trends in diuretics development","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112855","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112855"}}